Indications
Lumevoq (lenadogene nolparvovec) is indicated for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by a confirmed G11778A mutation in the ND4 mitochondrial gene (see section 5.1).
Composition
- Active substance
- lenadogene nolparvovec
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lumevoq
- Active substance
- lenadogene nolparvovec
- ATC code
- S01
- Group
- Sensory organs
- Therapeutic area
- Optic Atrophy, Hereditary, Leber
- Marketing authorisation holder
- GenSight Biologics S.A.
- Status
- Application withdrawn